Insulin Pump Tandem denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for insulin pump tandem are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issues an "Experimental" Denial for a Tandem Insulin Pump

Cigna's experimental/investigational denial for a Tandem insulin pump most commonly targets specific features or configurations of the device — particularly advanced closed-loop or automated insulin delivery (AID) system functionality — rather than the pump itself in its most basic form. Cigna may classify a specific algorithm-driven control mode or a particular device model as experimental if its coverage policy has not been updated to reflect the most current FDA clearance status, or if the policy requires additional evidence criteria that the submission did not address.

This denial type is often a policy-lag issue: the device or feature has FDA clearance, but Cigna's internal coverage policy has not yet been updated to reflect it, or the specific configuration ordered is not yet explicitly addressed in the published policy.

## Why This Denial Is Appealable

• Internal appeal (ACA §2719 / ERISA §503): Submit a full-and-fair internal appeal within the timeframe on the denial letter, centered on FDA clearance and evidence of clinical acceptance.
• External review: After the internal process, independent external review under ACA §2719 is available and the reviewer's decision is binding. The external-review window is generally within four months of the final internal denial.
• Expedited review: Available for urgent clinical situations.

## Documentation to Gather

1. FDA clearance: Download the FDA's public clearance documentation for the specific Tandem device model and any closed-loop algorithm (such as Control-IQ or similar) from fda.gov and attach it to the appeal. FDA clearance directly contradicts an experimental classification. 2. Guideline organization support: Note that the applicable diabetes specialist society guideline organizations (such as those referenced in the American Diabetes Association's standards of care) address automated insulin delivery technology — without citing specific numbers or statistics from those guidelines. 3. Clinical necessity for this patient: Chart notes and a prescriber letter documenting why this specific device and its features are medically necessary — including hypoglycemia history, glycemic variability, or other clinical factors. 4. Cigna's own policy language: Obtain Cigna's current published medical policy for insulin infusion pumps and identify the exact language used to classify the device as experimental. If the policy is outdated relative to FDA clearance, note the discrepancy explicitly. 5. Peer-reviewed literature: The prescriber can cite that this technology has been evaluated in peer-reviewed publications and is used in standard clinical practice — without citing specific trial names, statistics, or effect sizes.

## Criteria-Mapping Structure

| Cigna Experimental Criterion | Rebuttal Evidence | |---|---| | [Copy the experimental/investigational finding verbatim from the denial] | [FDA clearance documentation, date of clearance, and clinical necessity letter] | | [Any additional policy criteria] | [Supporting chart evidence] |